Australia unites taking small steps to make a big difference for melanoma research
23 March 2016
Melanoma March events have been an outstanding success across the country, with more than 6,000 dedicated supporters turning out for marches across 23 locations over the last month. Well over $600,000 has been raised, with two weeks of the campaign still remaining.
The Melbourne event, held early in March, attracted around 1,500 supporters, while 800 turned out for the Brisbane march last weekend. Over 700 supporters, including NSW Premier Mike Baird and rugby legend John Eales, braved the ominous clouds at Manly, while the inaugural march in Penrith attracted 500 people.
A team of volunteers and MIA staff ensured the events ran smoothly, arriving on site well before dawn to help set up, managing registrations, selling merchandise and staying back to pack up after events. MIA’s clinicians also attended events sharing their clinical insights and experiences with local crowds.
MIA’s CEO Carole Renouf who walked at the Wollongong and Manly marches said: “It takes an incredible amount of work behind the scenes to ensure events go to plan. We couldn’t do it without our incredible volunteers including staff members who took time out of their weekends to help. It was a real team effort and it was fantastic to see so many staff involved.
“I’d also like to thank our patients who bravely shared their stories with media and spoke at events. I was moved and inspired to hear about their experiences. They are the reason we do what we do.”
The final Melanoma March will be in Darwin on Sunday 10 April.
This International Clinical Trials Day we reflect on the importance of clinical trials and the people who dedicate their lives to helping melanoma patients today and in the future.
MIA has launched its first eBook Melanoma Essentials – A Concise Guide, a resource for GPs and other medical, nursing and allied professionals to help them effectively diagnose and manage cases.
Dr Scot Ebbinghaus chats to us about an exciting clinical trial at MIA and where melanoma treatment is headed in the future.
A new melanoma treatment has been listed on the PBS today, giving another option for advanced melanoma patients.
MIA's Pathology Fellow Dr Louise Jackett tells us why she's joined our fellowship program to learn from the best.
MIA doctors and patient have featured in the final episode of ABC’s ground-breaking series Keeping Australia Alive.
Specialist dermatologists at MIA are researching moles during pregnancy and we are looking for study recruits.
New research is re-writing the textbooks on what we know about melanoma by highlighting the effectiveness of radiotherapy as a treatment, reversing a long-held belief that melanoma was resistant to radiotherapy.
However, Australia's burden of melanoma will stay very high over the next 15 years unless we do more. MIA's Professor Graham Mann explains.
Thank you to everyone involved in making Melanoma March 2016 a huge success
Melanoma March 2016 has officially begun with more than 300 people marching in Rockingham and Devonport.
MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.
In the wake of Susie Maroney's recent announcement that she is battling melanoma, CEO Carole Renouf's opinion piece weighs in on the critical need we have in Australia to raise awareness about melanoma.
MIA's Georgina Long has been appointed Professor and awarded a coverted prize in medial research.
Melanoma March 2016 funding will be used to initiate an ambitious new project that will support the best possible care for melanoma patients around Australia through a new data and communication platform.
New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
New MIA-led research has been published in the Journal of Clinical Oncology.
Melanoma March was officially launched today with the announcement of the national research project funded by the march.
Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.
Maddison, the face of our Melanoma March campaign, knows the far-reaching effects that melanoma can have.
MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen.